US3400019A
(en)
*
|
1961-12-26 |
1968-09-03 |
Pullman Inc |
Electrode including nonmetallic substrate
|
US4518584A
(en)
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
US5116943A
(en)
|
1985-01-18 |
1992-05-26 |
Cetus Corporation |
Oxidation-resistant muteins of Il-2 and other protein
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
EP0368684B2
(en)
|
1988-11-11 |
2004-09-29 |
Medical Research Council |
Cloning immunoglobulin variable domain sequences.
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
US5081235A
(en)
|
1989-07-26 |
1992-01-14 |
City Of Hope |
Chimeric anti-cea antibody
|
WO1991003493A1
(en)
|
1989-08-29 |
1991-03-21 |
The University Of Southampton |
Bi-or trispecific (fab)3 or (fab)4 conjugates
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
DK0564531T3
(da)
|
1990-12-03 |
1998-09-28 |
Genentech Inc |
Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
LU91067I2
(fr)
|
1991-06-14 |
2004-04-02 |
Genentech Inc |
Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
CA2372813A1
(en)
|
1992-02-06 |
1993-08-19 |
L.L. Houston |
Biosynthetic binding protein for cancer marker
|
US5229109A
(en)
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
JP3095175B2
(ja)
|
1992-11-13 |
2000-10-03 |
アイデック ファーマシューティカルズ コーポレイション |
B細胞リンパ腫の治療のためのヒトbリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US5798100A
(en)
|
1994-07-06 |
1998-08-25 |
Immunomedics, Inc. |
Multi-stage cascade boosting vaccine
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
EP0831880A4
(en)
|
1995-06-07 |
2004-12-01 |
Imclone Systems Inc |
ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
US7727761B2
(en)
|
1995-08-01 |
2010-06-01 |
Vegenics Limited |
Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
|
FR2757863B1
(fr)
|
1996-12-27 |
1999-03-26 |
Inovat Sarl |
Nouvelles substances a activite biologique, leur procede d'obtention et les compositions en renfermant
|
DK0979281T3
(da)
|
1997-05-02 |
2005-11-21 |
Genentech Inc |
Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
IL136544A0
(en)
|
1997-12-05 |
2001-06-14 |
Scripps Research Inst |
Humanization of murine antibody
|
CA2317727C
(en)
|
1998-01-23 |
2013-01-08 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Multipurpose antibody derivatives
|
DK1071700T3
(da)
|
1998-04-20 |
2010-06-07 |
Glycart Biotechnology Ag |
Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
DK2270150T4
(da)
|
1999-04-09 |
2019-08-26 |
Kyowa Hakko Kirin Co Ltd |
Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle.
|
MXPA02000419A
(es)
*
|
1999-07-12 |
2004-09-10 |
Genentech Inc |
Bloqueo de la respuesta inmune a un antigeno extrano utilizando un antagonista que se enlaza a cd20.
|
EP1240319A1
(en)
|
1999-12-15 |
2002-09-18 |
Genentech, Inc. |
Shotgun scanning, a combinatorial method for mapping functional protein epitopes
|
CA2395660A1
(en)
|
1999-12-29 |
2001-07-12 |
Immunogen, Inc. |
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
|
CN101289511A
(zh)
|
2000-04-11 |
2008-10-22 |
杰南技术公司 |
多价抗体及其应用
|
WO2002009573A2
(en)
|
2000-07-31 |
2002-02-07 |
The Brigham And Women's Hospital, Inc. |
Prognostic classification of endometrial cancer
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
DE60131456T2
(de)
|
2000-11-30 |
2008-07-10 |
Medarex, Inc., Milpitas |
Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
|
KR20100018071A
(ko)
|
2001-08-03 |
2010-02-16 |
글리카트 바이오테크놀로지 아게 |
항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체
|
JP2005507870A
(ja)
|
2001-08-13 |
2005-03-24 |
ユニバーシティ・オブ・サザン・カリフォルニア |
低毒性のインターロイキン−2突然変異体
|
KR100988949B1
(ko)
|
2001-10-25 |
2010-10-20 |
제넨테크, 인크. |
당단백질 조성물
|
EP1454138B1
(en)
|
2001-12-04 |
2012-01-18 |
Merck Patent GmbH |
Immunocytokines with modulated selectivity
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
US8932825B2
(en)
|
2001-12-27 |
2015-01-13 |
Glycofi Inc. |
Method to engineer mammalian-type carbohydrate structures
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
JPWO2003085118A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物の製造方法
|
CA2481657A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells of which genome is modified
|
US7749753B2
(en)
|
2002-04-09 |
2010-07-06 |
Kyowa Hakko Kirin Co., Ltd |
Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
|
US20050031613A1
(en)
|
2002-04-09 |
2005-02-10 |
Kazuyasu Nakamura |
Therapeutic agent for patients having human FcgammaRIIIa
|
AU2003236018A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
|
NZ556507A
(en)
|
2002-06-03 |
2010-03-26 |
Genentech Inc |
Synthetic antibody phage libraries
|
PT1539966E
(pt)
|
2002-09-12 |
2010-09-14 |
Greenovation Biotech Gmbh |
Método de produção de proteínas
|
PL216630B1
(pl)
|
2002-10-17 |
2014-04-30 |
Genmab As |
Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
|
ES2347241T3
(es)
|
2002-12-16 |
2010-10-27 |
Genentech, Inc. |
Variantes de inmunoglobulina y sus utilizaciones.
|
JP4559358B2
(ja)
|
2002-12-20 |
2010-10-06 |
グリーンオベーション バイオテク ゲーエムベーハー |
コケ細胞における異種グリコシル化タンパク質の産生
|
JP2006524039A
(ja)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス,インコーポレーテッド |
変異型Fc領域を含む抗体の同定および作製ならびにその利用法
|
AU2004205631A1
(en)
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
CA2513797C
(en)
|
2003-01-22 |
2016-05-03 |
Glycart Biotechnology Ag |
Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
|
EP1629012B1
(en)
|
2003-05-31 |
2018-11-28 |
Amgen Research (Munich) GmbH |
Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
|
EP2292664B1
(en)
|
2003-10-16 |
2016-11-23 |
Amgen Research (Munich) GmbH |
Multispecific deimmunized CD3-binders
|
US9296820B2
(en)
|
2003-11-05 |
2016-03-29 |
Roche Glycart Ag |
Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
|
ES2697327T3
(es)
|
2003-11-06 |
2019-01-23 |
Seattle Genetics Inc |
Compuesto intermedio para la preparación de conjugados que comprenden derivados de auristatina y un enlazador
|
EP2186527A1
(en)
|
2003-11-28 |
2010-05-19 |
Micromet AG |
Compositions comprising polypeptides
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
WO2005086875A2
(en)
|
2004-03-11 |
2005-09-22 |
City Of Hope |
A humanized anti-cea t84.66 antibody and uses thereof
|
CN1961003B
(zh)
|
2004-03-31 |
2013-03-27 |
健泰科生物技术公司 |
人源化抗TGF-β抗体
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
SG172616A1
(en)
|
2004-04-13 |
2011-07-28 |
Hoffmann La Roche |
Anti-p-selectin antibodies
|
EP1740946B1
(en)
|
2004-04-20 |
2013-11-06 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
WO2005118635A2
(en)
|
2004-06-03 |
2005-12-15 |
Novimmune S.A. |
Anti-cd3 antibodies and methods of use thereof
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ox40l抗體
|
AR051836A1
(es)
|
2004-11-30 |
2007-02-14 |
Centocor Inc |
Antagonistas de receptor 3 simil toll metodos y usos
|
ES2755976T3
(es)
|
2005-02-07 |
2020-04-24 |
Roche Glycart Ag |
Moléculas de unión a antígeno que se unen a EGFR, vectores que las codifican y usos de las mismas
|
EP3050963B1
(en)
|
2005-03-31 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
US8475794B2
(en)
*
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
WO2006114115A1
(de)
|
2005-04-26 |
2006-11-02 |
Trion Pharma Gmbh |
Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
|
KR101498834B1
(ko)
|
2005-05-09 |
2015-03-05 |
오노 야꾸힝 고교 가부시키가이샤 |
예정 사멸 인자 1(pd-1)에 대한 인간 모노클로날 항체, 및 항-pd-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
|
CN101228189A
(zh)
|
2005-05-09 |
2008-07-23 |
格黎卡特生物技术股份公司 |
具有修饰的fc区域和改变的与fc受体的结合的抗原结合分子
|
HUE026039T2
(en)
|
2005-07-01 |
2016-05-30 |
Squibb & Sons Llc |
Human monoclonal antibodies programmed for death ligand 1 (PD-L1)
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
KR20140053410A
(ko)
|
2005-08-19 |
2014-05-07 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
AR055137A1
(es)
|
2005-08-26 |
2007-08-08 |
Glycart Biotechnology Ag |
Moleculas de union al antigeno modificadas con actividad de senalizacion celular alterada
|
EP1940881B1
(en)
|
2005-10-11 |
2016-11-30 |
Amgen Research (Munich) GmbH |
Compositions comprising cross-species-specific antibodies and uses thereof
|
EP2465870A1
(en)
|
2005-11-07 |
2012-06-20 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
|
EP1973951A2
(en)
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
CA2633486C
(en)
|
2005-12-16 |
2015-02-03 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
WO2007071422A2
(en)
|
2005-12-21 |
2007-06-28 |
Micromet Ag |
Pharmaceutical antibody compositions with resistance to soluble cea
|
KR101287777B1
(ko)
|
2005-12-21 |
2013-07-23 |
암젠 리서치 (뮌헨) 게엠베하 |
가용성 cea에 대한 내성을 가지는 약학적 조성물
|
AR060070A1
(es)
|
2006-03-24 |
2008-05-21 |
Merck Patent Gmbh |
Dominios proteicos heterodimericos obtenidos por ingenieria
|
EP2016101A2
(en)
|
2006-05-09 |
2009-01-21 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
SG172698A1
(en)
|
2006-06-12 |
2011-07-28 |
Trubion Pharmaceuticals Inc |
Single-chain multivalent binding proteins with effector function
|
JP2009541275A
(ja)
|
2006-06-22 |
2009-11-26 |
ノボ・ノルデイスク・エー/エス |
二重特異性抗体の生産
|
DK2059533T3
(da)
|
2006-08-30 |
2013-02-25 |
Genentech Inc |
Multispecifikke antistoffer
|
DK2066796T3
(da)
|
2006-09-20 |
2011-10-03 |
Mt Biomethan Gmbh |
Fremgangsmåde og indretning til fraskillelse af methan og kuldioxid fra biogas
|
HUE040467T2
(hu)
|
2007-04-03 |
2019-03-28 |
Amgen Res Munich Gmbh |
Keresztfaj-specifikus kötõdomén
|
WO2008119566A2
(en)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific bispecific binders
|
CN101687915B8
(zh)
|
2007-04-03 |
2018-08-03 |
安进研发(慕尼黑)股份有限公司 |
跨物种特异性CD3-ε结合结构域
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
WO2009061853A2
(en)
|
2007-11-05 |
2009-05-14 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (il-2) polypeptides
|
WO2009070642A1
(en)
|
2007-11-28 |
2009-06-04 |
Medimmune, Llc |
Protein formulation
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
DK2235064T3
(en)
|
2008-01-07 |
2016-01-11 |
Amgen Inc |
A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
|
ES2639857T3
(es)
|
2008-02-11 |
2017-10-30 |
Cure Tech Ltd. |
Anticuerpos monoclonales para el tratamiento del tumor
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
WO2009134738A1
(en)
*
|
2008-04-29 |
2009-11-05 |
Genentech, Inc. |
Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
TWI686405B
(zh)
|
2008-12-09 |
2020-03-01 |
建南德克公司 |
抗pd-l1抗體及其於增進t細胞功能之用途
|
CN102369215B
(zh)
|
2009-04-02 |
2015-01-21 |
罗切格利卡特公司 |
包含全长抗体和单链Fab片段的多特异性抗体
|
PT2417156E
(pt)
|
2009-04-07 |
2015-04-29 |
Roche Glycart Ag |
Anticorpos trivalentes, biespecíficos
|
EP2424567B1
(en)
|
2009-04-27 |
2018-11-21 |
OncoMed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
SG176219A1
(en)
|
2009-05-27 |
2011-12-29 |
Hoffmann La Roche |
Tri- or tetraspecific antibodies
|
EP2261258A1
(de)
|
2009-06-08 |
2010-12-15 |
Schuler, Gerold |
MCSP-gerichtete scFv-Antikörperfragmente und deren Verwendung
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
US8703132B2
(en)
|
2009-06-18 |
2014-04-22 |
Hoffmann-La Roche, Inc. |
Bispecific, tetravalent antigen binding proteins
|
KR101528013B1
(ko)
|
2009-08-31 |
2015-06-16 |
로슈 글리카트 아게 |
친화성-성숙된 인간화된 항-cea 단일클론 항체
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
KR101790767B1
(ko)
|
2009-11-24 |
2017-10-26 |
메디뮨 리미티드 |
B7―h1에 대한 표적화된 결합 물질
|
US20130017199A1
(en)
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
CN103124743A
(zh)
|
2009-12-29 |
2013-05-29 |
新兴产品开发西雅图有限公司 |
Ron结合构建物及其使用方法
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
WO2011143545A1
(en)
|
2010-05-14 |
2011-11-17 |
Rinat Neuroscience Corporation |
Heterodimeric proteins and methods for producing and purifying them
|
DK2635607T3
(da)
|
2010-11-05 |
2019-11-18 |
Zymeworks Inc |
Stabilt heterodimert antistofdesign med mutationer i fc-domænet
|
EP4303237A3
(en)
|
2010-11-30 |
2024-03-27 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
KR101667096B1
(ko)
*
|
2011-02-10 |
2016-10-18 |
로슈 글리카트 아게 |
돌연변이 인터루킨-2 폴리펩티드
|
CN103403029B
(zh)
|
2011-03-02 |
2015-11-25 |
罗切格利卡特公司 |
抗cea抗体
|
AU2012234335B2
(en)
|
2011-03-29 |
2016-09-01 |
Roche Glycart Ag |
Antibody Fc variants
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
RU2600067C2
(ru)
|
2011-05-06 |
2016-10-20 |
Дзе Гавермент Оф Дзе Юнайтед Стейтс Оф Америка Эз Репрезентед Бай Дзе Секретари Оф Дзе Депармент Оф Хелс Энд Хьюман Сёрвисез |
Рекомбинантный иммунотоксин, нацеленный на мезотелин
|
CN103842383B
(zh)
|
2011-05-16 |
2017-11-03 |
健能隆医药技术(上海)有限公司 |
多特异性fab融合蛋白及其使用方法
|
KR102060389B1
(ko)
|
2011-05-21 |
2019-12-31 |
마크로제닉스, 인크. |
사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자
|
US20140242081A1
(en)
|
2011-07-18 |
2014-08-28 |
Micromet Ag |
Dosing regimens for treatment of cea-expressing cancers
|
EP3321286B1
(en)
|
2011-08-23 |
2021-01-06 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules
|
WO2013026837A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
WO2013026835A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab fragments and methods of use
|
TW201326212A
(zh)
|
2011-08-23 |
2013-07-01 |
Roche Glycart Ag |
抗-mcsp抗體
|
BR112014004168A2
(pt)
|
2011-08-23 |
2017-12-12 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção
|
MX2014002053A
(es)
|
2011-08-23 |
2014-04-25 |
Roche Glycart Ag |
Anticuerpos anti -mcsp y metodos de uso.
|
SG2014008577A
(en)
|
2011-08-23 |
2014-04-28 |
Roche Glycart Ag |
Bispecific antigen binding molecules
|
EP2578230A1
(en)
|
2011-10-04 |
2013-04-10 |
Trion Pharma Gmbh |
Removal of Tumor Cells from Intraoperative Autologous Blood Salvage
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
JP6541974B2
(ja)
|
2011-12-20 |
2019-07-10 |
メディミューン,エルエルシー |
二重特異的抗体足場用改変ポリペプチド
|
US9248181B2
(en)
|
2012-04-20 |
2016-02-02 |
Merus B.V. |
Methods and means for the production of Ig-like molecules
|
US10202452B2
(en)
|
2012-04-20 |
2019-02-12 |
Aptevo Research And Development Llc |
CD3 binding polypeptides
|
EP2892924B1
(en)
|
2012-06-14 |
2020-11-25 |
Therapix Biosciences Ltd. |
Humanized antibodies to cluster of differentiation 3 (cd3)
|
US10301389B2
(en)
|
2012-06-15 |
2019-05-28 |
Imaginab, Inc. |
Antigen binding constructs to CD3
|
US20150203591A1
(en)
|
2012-08-02 |
2015-07-23 |
Regeneron Pharmaceuticals, Inc. |
Mutivalent antigen-binding proteins
|
JP6290209B2
(ja)
|
2012-08-07 |
2018-03-07 |
ロシュ グリクアート アーゲー |
低下した及び増加したエフェクター機能を有するように操作された2つの抗体を含む組成物。
|
WO2014028560A2
(en)
|
2012-08-14 |
2014-02-20 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
KR20150064068A
(ko)
*
|
2012-10-08 |
2015-06-10 |
로슈 글리카트 아게 |
2개의 Fab 단편을 포함하는 FC-부재 항체 및 이용 방법
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
EP2943511B1
(en)
|
2013-01-14 |
2019-08-07 |
Xencor, Inc. |
Novel heterodimeric proteins
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US10077315B2
(en)
|
2013-02-05 |
2018-09-18 |
Engmab Sàrl |
Bispecific antibodies against CD3 and BCMA
|
JO3529B1
(ar)
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
JP6499087B2
(ja)
|
2013-02-26 |
2019-04-10 |
ロシュ グリクアート アーゲー |
二重特異性t細胞活性化抗原結合分子
|
WO2014131711A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
EP2961771B1
(en)
|
2013-02-26 |
2020-01-01 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules specific to cd3 and cea
|
US10351626B2
(en)
|
2013-03-14 |
2019-07-16 |
The Scripps Research Institute |
Targeting agent antibody conjugates and uses thereof
|
JP6541581B2
(ja)
|
2013-03-15 |
2019-07-10 |
グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited |
低濃度抗体製剤
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
US20140302037A1
(en)
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
LT2951203T
(lt)
|
2013-03-15 |
2019-09-10 |
Xencor, Inc. |
Heterodimeriniai baltymai
|
EP2789630A1
(en)
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispecific antibodies against CD3e and ROR1
|
JP2016520600A
(ja)
|
2013-05-28 |
2016-07-14 |
ヌマブ アクチェンゲゼルシャフト |
新規抗体
|
UA119646C2
(uk)
|
2013-07-05 |
2019-07-25 |
Ґенмаб А/С |
Гуманізоване антитіло, що зв`язується з сd3 людини
|
MX2016007972A
(es)
|
2013-12-17 |
2016-10-28 |
Genentech Inc |
Metodos para tratar canceres con antagonistas de union al eje pd-1 y taxanos.
|
PE20210648A1
(es)
|
2013-12-17 |
2021-03-26 |
Genentech Inc |
Anticuerpos anti-cd3 y metodos de uso
|
CN105899535A
(zh)
|
2013-12-17 |
2016-08-24 |
豪夫迈·罗氏有限公司 |
用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法
|
JP6557664B2
(ja)
|
2014-01-06 |
2019-08-07 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
一価の血液脳関門シャトルモジュール
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
JP2017521998A
(ja)
|
2014-05-12 |
2017-08-10 |
ヌマブ アクチェンゲゼルシャフト |
新規多重特異性分子及びかかる多重特異性分子に基づく新規治療方法
|
CA2942453A1
(en)
|
2014-05-28 |
2015-12-03 |
F. Hoffmann-La Roche Ag |
Antibodies binding to human and cynomolgus cd3 epsilon
|
CN107108738A
(zh)
|
2014-07-25 |
2017-08-29 |
西托姆克斯治疗公司 |
抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法
|
KR102317315B1
(ko)
|
2014-08-04 |
2021-10-27 |
에프. 호프만-라 로슈 아게 |
이중특이적 t 세포 활성화 항원 결합 분자
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
EP2982693A1
(en)
|
2014-08-07 |
2016-02-10 |
Affimed Therapeutics AG |
CD3 binding domain
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
CA2951604A1
(en)
|
2014-08-29 |
2016-03-03 |
Pablo Umana |
Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
|
WO2016036678A1
(en)
|
2014-09-02 |
2016-03-10 |
Medimmune, Llc |
Formulations of bispecific antibodies
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
CA2963696A1
(en)
|
2014-10-09 |
2016-04-14 |
Engmab Ag |
Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
|
WO2016055592A1
(en)
|
2014-10-09 |
2016-04-14 |
Engmab Ag |
Bispecific antibodies against cd3epsilon and ror1
|
PL3221356T3
(pl)
|
2014-11-20 |
2021-01-11 |
F. Hoffmann-La Roche Ag |
Wiążące antygen dwuswoiste cząsteczki przeciwko folr1 i cd3 aktywujące limfocyty t
|
WO2016079081A1
(en)
|
2014-11-20 |
2016-05-26 |
F. Hoffmann-La Roche Ag |
Common light chains and methods of use
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
JP2018520642A
(ja)
|
2015-05-01 |
2018-08-02 |
ジェネンテック, インコーポレイテッド |
マスク抗cd3抗体及びその使用方法
|
SI3310814T1
(sl)
|
2015-06-16 |
2023-11-30 |
F. Hoffmann - La Roche Ag |
HUMANIZIRANA IN AFINITETNO DOZORELA PROTITELESA PROTI FcRH5 IN METODE ZA NJIHOVO UPORABO
|
PT3331910T
(pt)
|
2015-08-03 |
2020-03-24 |
Engmab Sarl |
Anticorpos monoclonais contra o antigénio de maturação de células b (bcma) humano
|
EP3356410B1
(en)
|
2015-10-02 |
2021-10-20 |
F. Hoffmann-La Roche AG |
Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
|
US20170096485A1
(en)
|
2015-10-02 |
2017-04-06 |
Hoffmann-La Roche Inc. |
Bispecific t cell activating antigen binding molecules
|
WO2017055318A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Cd33xcd3 bispecific t cell activating antigen binding molecules
|
CN107949574A
(zh)
|
2015-10-02 |
2018-04-20 |
豪夫迈·罗氏有限公司 |
双特异性t细胞活化性抗原结合分子
|
WO2017055314A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
KR20180085740A
(ko)
|
2015-12-09 |
2018-07-27 |
에프. 호프만-라 로슈 아게 |
항-약물 항체의 형성을 감소시키기 위한 ii형 항-cd20 항체
|
US11466094B2
(en)
|
2016-11-15 |
2022-10-11 |
Genentech, Inc. |
Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
|